nivolumabbrentuximab vedotinpembrolizumabcarboplatinpemetrexed
…9 life years; 95% CI 7929 to 8220; 10.8%; figure 4). The use of nivolumab to treat melanoma, pembrolizumab to treat non-small cell lung c…
6articles mentioning drugs
29drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: cancer drugs ×
cancer drugs
This drug is selected. Its supporting articles are shown below.
Articles mentioning cancer drugs
6 articles · page 1 of 1cancer drugsmelanomaSEERprostatethyroid cancersFDAcancer
… often not assessed. Between 1992 and 2019, the FDA approved 64 cancer drugs based on surrogate endpoints. Of these, only 3 reported high co…
trastuzumabzoledronic acidlapatinibabirateroneoxaliplatincancer drugsCancer drugsimmunotherapeutic agentsrenal cell carcinomabreast cancer+5 more
…vant therapy for oxaliplatin in colon cancer or the duration of trastuzumab in breast cancer, FDA labels are not regularly updated,25 and t…
cancer drugsFDAUS Food and Drug Administrationpublic insurers
…to approve cancer drugs.1 2 In 2017, the percentage of approved cancer drugs demonstrating improvement in overall survival (OS) fell to 7% (…
cancer drugsUS Food and Drug AdministrationFDANCCN guidelines
…appointment about the lack of availability and affordability of cancer drugs and wished for more representation of Indian patients in the pi…
Cancer DrugsKesselheim ASLiu ITTCliff ERSJAMA
…heim AS, Cliff ERS. Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval. JAMA. 2024;331:1471-9.…